Concepts (286)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Residence Characteristics | 14 | 2025 | 295 | 3.280 |
Why?
|
| Socioeconomic Factors | 12 | 2025 | 915 | 1.850 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2024 | 982 | 1.650 |
Why?
|
| Liver Neoplasms | 4 | 2024 | 1373 | 1.480 |
Why?
|
| Texas | 24 | 2026 | 3686 | 1.260 |
Why?
|
| Cyclonic Storms | 4 | 2023 | 82 | 1.130 |
Why?
|
| Transportation | 2 | 2019 | 26 | 0.990 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2024 | 269 | 0.980 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 895 | 0.860 |
Why?
|
| Schools | 6 | 2025 | 239 | 0.820 |
Why?
|
| Walking | 4 | 2019 | 230 | 0.780 |
Why?
|
| Registries | 8 | 2026 | 1634 | 0.780 |
Why?
|
| Environment Design | 4 | 2019 | 16 | 0.770 |
Why?
|
| Pediatric Obesity | 6 | 2025 | 419 | 0.770 |
Why?
|
| Floods | 3 | 2022 | 21 | 0.750 |
Why?
|
| Arsenic | 1 | 2023 | 48 | 0.740 |
Why?
|
| Health Status Disparities | 4 | 2024 | 282 | 0.720 |
Why?
|
| Social Class | 3 | 2025 | 214 | 0.650 |
Why?
|
| Disasters | 1 | 2021 | 101 | 0.600 |
Why?
|
| Public Facilities | 1 | 2019 | 1 | 0.590 |
Why?
|
| Bicycling | 1 | 2019 | 37 | 0.570 |
Why?
|
| Hypersensitivity | 1 | 2021 | 227 | 0.540 |
Why?
|
| Incidence | 8 | 2024 | 3360 | 0.540 |
Why?
|
| Geographic Information Systems | 2 | 2015 | 38 | 0.540 |
Why?
|
| Overweight | 1 | 2020 | 387 | 0.520 |
Why?
|
| Stress, Psychological | 2 | 2021 | 536 | 0.520 |
Why?
|
| Pandemics | 5 | 2023 | 1118 | 0.510 |
Why?
|
| Environmental Exposure | 3 | 2026 | 298 | 0.490 |
Why?
|
| Mexican Americans | 2 | 2015 | 162 | 0.480 |
Why?
|
| Exercise | 2 | 2019 | 892 | 0.440 |
Why?
|
| Humans | 56 | 2026 | 131163 | 0.430 |
Why?
|
| Female | 41 | 2026 | 70963 | 0.430 |
Why?
|
| Male | 45 | 2026 | 64957 | 0.430 |
Why?
|
| Communicable Disease Control | 5 | 2023 | 139 | 0.420 |
Why?
|
| Safety | 2 | 2016 | 215 | 0.420 |
Why?
|
| Social Determinants of Health | 2 | 2026 | 165 | 0.390 |
Why?
|
| Spatial Analysis | 2 | 2024 | 26 | 0.380 |
Why?
|
| Health Behavior | 4 | 2020 | 387 | 0.380 |
Why?
|
| Adult | 20 | 2026 | 31282 | 0.380 |
Why?
|
| Fenfluramine | 3 | 1997 | 12 | 0.340 |
Why?
|
| Motor Activity | 2 | 2014 | 489 | 0.340 |
Why?
|
| Venous Thromboembolism | 2 | 2025 | 195 | 0.330 |
Why?
|
| Middle Aged | 15 | 2026 | 28601 | 0.320 |
Why?
|
| Parents | 2 | 2016 | 1128 | 0.310 |
Why?
|
| Analgesics | 4 | 1994 | 120 | 0.290 |
Why?
|
| Aged | 11 | 2026 | 21025 | 0.280 |
Why?
|
| Cross-Sectional Studies | 7 | 2025 | 3829 | 0.270 |
Why?
|
| Adolescent | 16 | 2025 | 20987 | 0.270 |
Why?
|
| Healthcare Disparities | 2 | 2026 | 523 | 0.260 |
Why?
|
| Surveys and Questionnaires | 10 | 2024 | 4066 | 0.260 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2024 | 614 | 0.260 |
Why?
|
| United States | 14 | 2025 | 12072 | 0.250 |
Why?
|
| Child | 16 | 2025 | 26341 | 0.250 |
Why?
|
| Young Adult | 9 | 2025 | 10103 | 0.250 |
Why?
|
| Child, Preschool | 8 | 2024 | 15110 | 0.220 |
Why?
|
| Research Design | 5 | 2020 | 716 | 0.220 |
Why?
|
| Social Environment | 2 | 2016 | 113 | 0.220 |
Why?
|
| Sex Characteristics | 3 | 2023 | 323 | 0.220 |
Why?
|
| Data Mining | 1 | 2025 | 68 | 0.220 |
Why?
|
| Mouth Neoplasms | 1 | 2026 | 105 | 0.220 |
Why?
|
| Culex | 1 | 2024 | 32 | 0.210 |
Why?
|
| Natural Language Processing | 1 | 2025 | 76 | 0.210 |
Why?
|
| Mosquito Vectors | 1 | 2024 | 34 | 0.210 |
Why?
|
| Safety-net Providers | 1 | 2025 | 93 | 0.210 |
Why?
|
| Geography, Medical | 1 | 2023 | 15 | 0.200 |
Why?
|
| Serotonin | 2 | 1994 | 208 | 0.190 |
Why?
|
| Papillomavirus Vaccines | 1 | 2024 | 113 | 0.190 |
Why?
|
| Hypothalamus | 2 | 1994 | 206 | 0.190 |
Why?
|
| Hodgkin Disease | 1 | 2025 | 307 | 0.180 |
Why?
|
| Pain | 4 | 2022 | 450 | 0.180 |
Why?
|
| Wounds, Gunshot | 1 | 2024 | 148 | 0.180 |
Why?
|
| Endocrine Disruptors | 1 | 2022 | 55 | 0.180 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2025 | 229 | 0.180 |
Why?
|
| Peritoneal Dialysis | 1 | 2023 | 133 | 0.170 |
Why?
|
| Arginine Vasopressin | 2 | 1992 | 26 | 0.170 |
Why?
|
| Machine Learning | 1 | 2025 | 387 | 0.170 |
Why?
|
| Sociological Factors | 1 | 2021 | 9 | 0.170 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2022 | 82 | 0.170 |
Why?
|
| Workplace Violence | 1 | 2020 | 3 | 0.160 |
Why?
|
| Social Isolation | 1 | 2020 | 49 | 0.160 |
Why?
|
| Health Services Accessibility | 3 | 2025 | 712 | 0.160 |
Why?
|
| Program Evaluation | 3 | 2023 | 447 | 0.160 |
Why?
|
| Rectal Neoplasms | 1 | 2021 | 79 | 0.160 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 369 | 0.160 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 182 | 0.160 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 502 | 0.150 |
Why?
|
| House Calls | 1 | 2020 | 35 | 0.150 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 394 | 0.150 |
Why?
|
| Receptors, Serotonin | 2 | 1997 | 37 | 0.150 |
Why?
|
| Public Opinion | 1 | 2020 | 64 | 0.150 |
Why?
|
| Heart Defects, Congenital | 2 | 2022 | 1889 | 0.150 |
Why?
|
| Cities | 1 | 2019 | 51 | 0.140 |
Why?
|
| Stress, Physiological | 2 | 1991 | 259 | 0.140 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2021 | 210 | 0.140 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2019 | 134 | 0.140 |
Why?
|
| Colonic Neoplasms | 1 | 2021 | 262 | 0.140 |
Why?
|
| Outpatients | 1 | 2020 | 262 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2021 | 387 | 0.140 |
Why?
|
| Retrospective Studies | 8 | 2025 | 17753 | 0.140 |
Why?
|
| Survivors | 1 | 2020 | 344 | 0.140 |
Why?
|
| Health Status | 1 | 2020 | 378 | 0.140 |
Why?
|
| Social Media | 1 | 2020 | 120 | 0.140 |
Why?
|
| Educational Status | 2 | 2021 | 279 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2025 | 844 | 0.130 |
Why?
|
| Sarcoma, Kaposi | 1 | 2019 | 129 | 0.130 |
Why?
|
| Community Networks | 1 | 2017 | 30 | 0.130 |
Why?
|
| Interleukin-1 | 2 | 1995 | 130 | 0.130 |
Why?
|
| 5-Hydroxytryptophan | 1 | 1997 | 3 | 0.130 |
Why?
|
| Thiazepines | 1 | 1997 | 7 | 0.130 |
Why?
|
| Eating | 2 | 1997 | 377 | 0.130 |
Why?
|
| Mental Health | 1 | 2020 | 378 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 275 | 0.130 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 1997 | 29 | 0.130 |
Why?
|
| Appetite Depressants | 1 | 1997 | 23 | 0.130 |
Why?
|
| Fluoxetine | 1 | 1997 | 47 | 0.120 |
Why?
|
| Behavior, Animal | 3 | 1997 | 480 | 0.120 |
Why?
|
| Attitude to Health | 2 | 2015 | 247 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 464 | 0.120 |
Why?
|
| Hospitals | 1 | 2019 | 435 | 0.120 |
Why?
|
| Hypertension | 1 | 2025 | 1356 | 0.120 |
Why?
|
| Mice, Inbred Strains | 6 | 1995 | 263 | 0.120 |
Why?
|
| Renal Dialysis | 1 | 2023 | 951 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 339 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 351 | 0.110 |
Why?
|
| Indomethacin | 1 | 1995 | 79 | 0.110 |
Why?
|
| Prednisolone | 1 | 1995 | 74 | 0.110 |
Why?
|
| Neoplasms | 3 | 2024 | 3016 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 621 | 0.110 |
Why?
|
| Survival Rate | 1 | 2020 | 2114 | 0.110 |
Why?
|
| Norfenfluramine | 1 | 1994 | 1 | 0.110 |
Why?
|
| Environmental Health | 2 | 2026 | 22 | 0.110 |
Why?
|
| Family Relations | 1 | 2015 | 75 | 0.110 |
Why?
|
| Naloxone | 2 | 1991 | 45 | 0.100 |
Why?
|
| Physical Fitness | 1 | 2014 | 93 | 0.100 |
Why?
|
| School Health Services | 1 | 2015 | 103 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 5196 | 0.100 |
Why?
|
| Feeding and Eating Disorders | 1 | 1994 | 74 | 0.100 |
Why?
|
| Physicians | 1 | 2020 | 635 | 0.100 |
Why?
|
| Secondary Prevention | 1 | 2015 | 217 | 0.100 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1995 | 292 | 0.100 |
Why?
|
| Primary Prevention | 1 | 2015 | 183 | 0.100 |
Why?
|
| Receptors, Vasopressin | 1 | 1992 | 13 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1995 | 301 | 0.090 |
Why?
|
| Guidelines as Topic | 1 | 2014 | 198 | 0.090 |
Why?
|
| Dopamine | 1 | 1994 | 246 | 0.090 |
Why?
|
| Body Temperature Regulation | 1 | 1992 | 52 | 0.090 |
Why?
|
| Codeine | 1 | 1992 | 23 | 0.090 |
Why?
|
| Behavioral Medicine | 1 | 2011 | 11 | 0.090 |
Why?
|
| Morphine | 1 | 1992 | 81 | 0.090 |
Why?
|
| Students | 1 | 2014 | 250 | 0.090 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 1992 | 133 | 0.090 |
Why?
|
| Asthma | 1 | 2020 | 922 | 0.090 |
Why?
|
| Models, Educational | 1 | 2011 | 78 | 0.080 |
Why?
|
| Histamine | 1 | 1991 | 52 | 0.080 |
Why?
|
| Primary Health Care | 1 | 2017 | 775 | 0.080 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1990 | 5 | 0.080 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1990 | 37 | 0.080 |
Why?
|
| Prognosis | 1 | 2020 | 4886 | 0.080 |
Why?
|
| Peptide Fragments | 1 | 1994 | 687 | 0.080 |
Why?
|
| Longitudinal Studies | 3 | 2020 | 1490 | 0.080 |
Why?
|
| Analgesia | 1 | 1990 | 44 | 0.080 |
Why?
|
| Nociceptors | 1 | 1990 | 14 | 0.080 |
Why?
|
| Research Personnel | 1 | 2011 | 139 | 0.080 |
Why?
|
| Injections, Intraventricular | 4 | 1992 | 52 | 0.070 |
Why?
|
| Feeding Behavior | 1 | 1994 | 715 | 0.070 |
Why?
|
| Animals | 12 | 2024 | 33912 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 3 | 1997 | 1105 | 0.070 |
Why?
|
| Prevalence | 2 | 2025 | 2701 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2014 | 1717 | 0.070 |
Why?
|
| Inflammation | 1 | 1995 | 1489 | 0.070 |
Why?
|
| Brain | 2 | 1997 | 3175 | 0.060 |
Why?
|
| Pain Measurement | 3 | 1994 | 353 | 0.060 |
Why?
|
| Linear Models | 2 | 2021 | 688 | 0.060 |
Why?
|
| Sex Factors | 2 | 2021 | 1356 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2011 | 561 | 0.060 |
Why?
|
| Rats | 3 | 1997 | 3370 | 0.050 |
Why?
|
| Population Density | 1 | 2024 | 31 | 0.050 |
Why?
|
| Oil and Gas Fields | 1 | 2024 | 10 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2026 | 5063 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2025 | 3061 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2025 | 263 | 0.050 |
Why?
|
| Age Factors | 2 | 2021 | 2825 | 0.050 |
Why?
|
| Risk Factors | 3 | 2025 | 11074 | 0.050 |
Why?
|
| Mice | 8 | 1995 | 18301 | 0.050 |
Why?
|
| Community-Institutional Relations | 1 | 2023 | 31 | 0.050 |
Why?
|
| Firearms | 1 | 2024 | 59 | 0.050 |
Why?
|
| Sarcoma, Ewing | 1 | 2024 | 122 | 0.050 |
Why?
|
| West Nile Fever | 1 | 2024 | 145 | 0.050 |
Why?
|
| Feedback | 1 | 2023 | 144 | 0.050 |
Why?
|
| Travel | 1 | 2023 | 117 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2026 | 1287 | 0.050 |
Why?
|
| Injections, Intraperitoneal | 2 | 1994 | 65 | 0.050 |
Why?
|
| Silicones | 1 | 2022 | 31 | 0.050 |
Why?
|
| Focus Groups | 1 | 2023 | 239 | 0.050 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2022 | 64 | 0.050 |
Why?
|
| Poverty Areas | 1 | 2021 | 37 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2022 | 79 | 0.040 |
Why?
|
| Hepatoblastoma | 1 | 2024 | 204 | 0.040 |
Why?
|
| Marital Status | 1 | 2021 | 32 | 0.040 |
Why?
|
| Physical Exertion | 2 | 1991 | 63 | 0.040 |
Why?
|
| Logistic Models | 2 | 2016 | 1797 | 0.040 |
Why?
|
| Hysterectomy | 1 | 2023 | 202 | 0.040 |
Why?
|
| Emotions | 1 | 2023 | 350 | 0.040 |
Why?
|
| Hot Temperature | 2 | 1991 | 137 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2022 | 151 | 0.040 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2020 | 35 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1994 | 1618 | 0.040 |
Why?
|
| Workplace | 1 | 2020 | 80 | 0.040 |
Why?
|
| Fever | 1 | 2022 | 312 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2020 | 222 | 0.040 |
Why?
|
| Geography | 1 | 2019 | 114 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 1410 | 0.040 |
Why?
|
| Vaccination | 1 | 2024 | 1060 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 179 | 0.040 |
Why?
|
| Self Report | 1 | 2022 | 554 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 421 | 0.040 |
Why?
|
| Morbidity | 1 | 2019 | 256 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2025 | 2904 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 231 | 0.030 |
Why?
|
| Infant | 2 | 2024 | 13352 | 0.030 |
Why?
|
| Self-Management | 1 | 2020 | 120 | 0.030 |
Why?
|
| Public Health | 1 | 2020 | 269 | 0.030 |
Why?
|
| Life Style | 1 | 2021 | 456 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 236 | 0.030 |
Why?
|
| Serotonin Agents | 1 | 1997 | 14 | 0.030 |
Why?
|
| Neuropeptide Y | 1 | 1997 | 34 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 1997 | 106 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 689 | 0.030 |
Why?
|
| Dopamine Agonists | 1 | 1997 | 57 | 0.030 |
Why?
|
| Zymosan | 1 | 1995 | 3 | 0.030 |
Why?
|
| Exudates and Transudates | 1 | 1995 | 15 | 0.030 |
Why?
|
| Phenotype | 1 | 2025 | 4497 | 0.030 |
Why?
|
| Peroxidase | 1 | 1995 | 63 | 0.030 |
Why?
|
| Dinoprostone | 1 | 1995 | 65 | 0.030 |
Why?
|
| Formaldehyde | 2 | 1992 | 49 | 0.030 |
Why?
|
| Granuloma | 1 | 1995 | 59 | 0.030 |
Why?
|
| Fenclonine | 1 | 1994 | 1 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1595 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 919 | 0.030 |
Why?
|
| Microdialysis | 1 | 1994 | 59 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2015 | 93 | 0.030 |
Why?
|
| Administration, Oral | 2 | 1994 | 711 | 0.030 |
Why?
|
| Community-Based Participatory Research | 1 | 2015 | 65 | 0.030 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 1 | 1994 | 9 | 0.030 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 1994 | 28 | 0.030 |
Why?
|
| Food Deprivation | 1 | 1994 | 33 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 1994 | 116 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 1994 | 156 | 0.020 |
Why?
|
| Muscle Contraction | 1 | 1994 | 147 | 0.020 |
Why?
|
| Abdomen | 1 | 1994 | 126 | 0.020 |
Why?
|
| Pregnancy | 1 | 2026 | 7512 | 0.020 |
Why?
|
| Data Collection | 1 | 2015 | 370 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1995 | 639 | 0.020 |
Why?
|
| Body Weight | 1 | 1997 | 987 | 0.020 |
Why?
|
| Oxymorphone | 1 | 1992 | 1 | 0.020 |
Why?
|
| Receptors, Histamine | 1 | 1991 | 3 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1224 | 0.020 |
Why?
|
| Histamine Antagonists | 1 | 1991 | 16 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2014 | 320 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 1991 | 39 | 0.020 |
Why?
|
| Narcotic Antagonists | 1 | 1992 | 112 | 0.020 |
Why?
|
| Health Promotion | 1 | 2015 | 422 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2024 | 8635 | 0.020 |
Why?
|
| Models, Psychological | 1 | 2011 | 138 | 0.020 |
Why?
|
| Parenting | 1 | 2015 | 348 | 0.020 |
Why?
|
| Swimming | 1 | 1990 | 25 | 0.020 |
Why?
|
| Norepinephrine | 1 | 1990 | 149 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 2395 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2011 | 212 | 0.020 |
Why?
|
| Drug Interactions | 1 | 1990 | 237 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 2082 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 1994 | 3464 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2025 | 12936 | 0.020 |
Why?
|
| Reaction Time | 1 | 1990 | 152 | 0.020 |
Why?
|
| Cognition | 1 | 2014 | 829 | 0.020 |
Why?
|
| Arginine | 1 | 1991 | 340 | 0.020 |
Why?
|
| Anxiety | 1 | 2015 | 1014 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 1992 | 2085 | 0.020 |
Why?
|
| Diet | 1 | 1994 | 1121 | 0.020 |
Why?
|
| HIV Infections | 1 | 2019 | 2049 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 6797 | 0.010 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 1991 | 57 | 0.010 |
Why?
|
| Brain Chemistry | 1 | 1991 | 110 | 0.010 |
Why?
|
| Edema | 1 | 1991 | 130 | 0.000 |
Why?
|
| Nitric Oxide | 1 | 1991 | 471 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1991 | 1345 | 0.000 |
Why?
|